46 reports

One promising target for cancer treatment is the insulin-like growth factor ## receptor (IGF-##R).

  • Autoimmune Disease
  • China
  • Beijing Biotech Pharmaceutical Co., Ltd.
  • Beijing Tiantan Biological Products Co., Ltd.
  • Shanghai CP Guojian Pharmaceutical Co., Ltd.

You can easily book an appointment with one online.

  • Autoimmune Disease
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • 4A) CLINICAL SUCCESS OF ANTI-IL17 ANTIBODIES
  • 3) TARGET BACKGROUND

One of the company' s two lead programs targets RORgammaT.

  • Autoimmune Disease
  • United States
  • 4SC Discovery GmbH
  • Advinus
  • AstraZeneca PLC
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

As part of the randomized, double-blind, multicentre trial, patients were randomized in a ##:##:## ratio to receive PF- ##, PF-## or placebo.

  • Autoimmune Disease
  • United States
  • World
  • Product Initiative
  • Pfizer Inc.
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Encore presentation from the WCOG at ACG2017 ##.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

The study lasted for ## year.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • VTP-43742 - DRUG PROFILE

The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Autoimmune Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Lycera Corp.
  • 4. Drug/Molecule refers to Primary Intervention only.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Therapy
  • World
  • Product Initiative
  • Catalyst Pharmaceuticals, Inc.
  • VTP-43742 - DRUG PROFILE

Liraglutide is a glucagon-like peptide-## (GLP-##) receptor agonist.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Hospital
  • Therapy
  • World
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Alexion Pharmaceuticals Inc ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## Cytokinetics Inc ## ## ## ## ## ## ## Quintiles IMS Holdings Inc ## ## ## ## ## ## ## CuraVac Inc ## ## ## ## ## ## ## CSL Ltd ##

  • Autoimmune Disease
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Simbec Research Limited
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Pharmaceutical Product Development LLC ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## MallInckrodt Plc ## ## ## ## ## ## CSL Ltd ## ## ## ## ##

  • Autoimmune Disease
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Novartis AG

One confirmed relapse was reported, in Cohort ##.

  • Autoimmune Disease
  • Neurological Disorder
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

As of April 2009, the drug candidate was in Phase II/ III stage of development for rasmussen s encephalitis.

  • Autoimmune Disease
  • Neurological Disorder
  • United States
  • Product Initiative
  • Pfizer Inc.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Novartis AG
  • MYASTHENIA GRAVIS - PIPELINE BY ALPHA CANCER TECHNOLOGIES INC, H1 2018
  • MYASTHENIA GRAVIS - PIPELINE BY APELLIS PHARMACEUTICALS INC, H1 2018

The company provides treatment of myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Autoimmune Disease
  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • ALPHA CANCER TECHNOLOGIES INC
  • MYASTHENIA GRAVIS - PIPELINE BY ALPHA CANCER TECHNOLOGIES INC, H2 2018

The company provides treatment for myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Protalex, Inc.

NARA-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description NARA-## ANAVEON AG NA NA NARA-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF MELANOMA, KIDNEY CANCER AND LUNG CANCER.

  • Autoimmune Disease
  • United States
  • World
  • Product Initiative
  • Philogen S.p.A.
  • Clinical Trial profile. 175 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Cardiology
  • Clinical Trial
  • Monoclonal Antibody
  • World

SR ONE LTD.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • AbbVie Inc.
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

The study lasted for ## year.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

## Phase I ## ## Preclinical ## ## Discovery ## ## Total ## ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Stage of Develop

  • Autoimmune Disease
  • Health Services
  • Therapy
  • United States
  • Product Initiative

In the study, ## patients were randomized ##:##:## to receive placebo, baricitinib ## mg or baricitinib ## mg.

  • Autoimmune Disease
  • Cell Therapy
  • Musculoskeletal Disorder
  • World
  • GlaxoSmithKline plc

Kidney Transplant Rejection - Overview Kidney Transplant Rejection - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Pre-Registration ## ## Ph

  • Autoimmune Disease
  • Healthcare
  • Therapy
  • United States
  • Product Initiative

Fourteen patients developed ## grade ## toxicities, including lymphopenia in ## patients, hyperglycemia in ##, ALT elevation in ##, thrombocytopenia in ##, lung infection in ##, AST elevation in ##, neutropenia in ##, urinary tract infection in ##, colitis in ##, febrile ne

  • Autoimmune Disease
  • Healthcare
  • Monoclonal Antibody
  • United States
  • Product Initiative

Fourteen patients developed ## grade ## toxicities, including lymphopenia in ## patients, hyperglycemia in ##, ALT elevation in ##, thrombocytopenia in ##, lung infection in ##, AST elevation in ##, neutropenia in ##, urinary tract infection in ##, colitis in ##, febrile ne

  • Autoimmune Disease
  • Cell Therapy
  • Specialty Hospital
  • Transplantation
  • Pluristem Therapeutics Inc.

As of April 2009, the drug candidate was in Phase II/ III stage of development for rasmussen s encephalitis.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • AB Science SA
  • TOLERANCE AS A POTENTIAL MECHANISM OF ACTION PROVIDING SUCH LONG-LASTING THERAPEUTIC POTENTIAL.

AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL ESCALIER BIOSCIENCES BV EVELO BIOSCIENCES INC EXICURE INC FUJIFILM KYOWA KIRIN BIOLOGICS CO LTD GALAPAGOS NV GALDERMA SA INNOVIMMUNE BIOTHERAPEUTICS INC JAPAN TOBACCO INC KV##. ## THERAPEUTICS LUPIN LTD PR ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Autoimmune Disease
  • Biotech
  • United States
  • Company
  • Product Initiative
  • VTP-43742 - DRUG PROFILE

In the experimental autoimmune encephalitis mouse model of MS, short term treatments with CGEN-## resulted in a long term dramatic improvement of disease symptoms.

  • Autoimmune Disease
  • Biotech
  • United States
  • Company
  • Product Initiative